Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kailera Therapeutics, Inc. - Common stock (NQ:KLRA)

12.83 -0.09 (-0.70%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,164,418
Open 12.98
Bid (Size) 12.82 (900)
Ask (Size) 12.85 (1,000)
Prev. Close 12.92
Today's Range 12.36 - 13.23
52wk Range 12.36 - 28.23
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Kailera Therapeutics to Participate in September Investor Conferences
From Kailera Therapeutics, Inc.
Via GlobeNewswire
News headline image
2 GLP-1 Stocks That Could Double Your Money by 2031 ↗
They are fairly risky, but their potential upside is massive. 
Via The Motley Fool

Performance

YTD
-50.7%
-50.7%
1 Month
-26.5%
-26.5%
3 Month
-43.9%
-43.9%
6 Month
-50.7%
-50.7%
1 Year
-50.7%
-50.7%

More News

Read More
News headline image
Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates
From Kailera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kailera Therapeutics Appoints Nur Nicholson as Chief Technology Officer
From Kailera Therapeutics, Inc.
Via GlobeNewswire
News headline image
2 Beaten-Down GLP-1 Stocks to Buy on the Dip ↗
Via The Motley Fool
News headline image
Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535
From Kailera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pfizer's CEO Says His Company Has a "Very Big Balance Sheet" to Do Deals. Here's the Perfect Next Acquisition Target for the Pharma Giant ↗
Via The Motley Fool
News headline image
3 Under-the-Radar Stocks to Buy and Hold for a Decade ↗
Via The Motley Fool
News headline image
Parabilis Soared 58% in the Biggest Biotech IPO on Record. Is It Too Late to Buy the Stock? ↗
Via The Motley Fool
Topics Initial Public Offering
News headline image
Kailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
From Kailera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates
From Kailera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Is Kailera Therapeutics a Buy After Its Sizzling IPO? ↗
Via The Motley Fool
Topics Initial Public Offering
News headline image
A Kailera Therapeutics (KLRA) Insider Scooped up an Additional 500,000 Shares for $8.0 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Kailera Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Kailera Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Kailera Therapeutics, Inc. - Common stock publicly traded?
Yes, Kailera Therapeutics, Inc. - Common stock is publicly traded.
What exchange does Kailera Therapeutics, Inc. - Common stock trade on?
Kailera Therapeutics, Inc. - Common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Kailera Therapeutics, Inc. - Common stock?
The ticker symbol for Kailera Therapeutics, Inc. - Common stock is KLRA on the Nasdaq Stock Market
What is the current price of Kailera Therapeutics, Inc. - Common stock?
The current price of Kailera Therapeutics, Inc. - Common stock is 12.83
When was Kailera Therapeutics, Inc. - Common stock last traded?
The last trade of Kailera Therapeutics, Inc. - Common stock was at 09/18/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.